Cholangiocarcinoma — novel biological insights and therapeutic strategies

Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17, 557–588 (2020). 10.1038/s41575-020-0310-z

[4]

Cholangiocarcinoma — evolving concepts and therapeutic strategies

Sumera I. Ilyas, Shahid A. Khan, Christopher L. Hallemeier et al.

Nature Reviews Clinical Oncology 2018 10.1038/nrclinonc.2017.157

[5]

Affo, S. et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell 39, 883 (2021). 10.1016/j.ccell.2021.05.010

[6]

Yang, J. D. et al. DNA methylation markers for detection of cholangiocarcinoma: discovery, validation, and clinical testing in biliary brushings and plasma. Hepatol. Commun. 5, 1448–1459 (2021). 10.1002/hep4.1730

[7]

Zill, O. A. et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 5, 1040–1048 (2015). 10.1158/2159-8290.cd-15-0274

[8]

Wu, M. J., Shi, L., Merritt, J., Zhu, A. X. & Bardeesy, N. Biology of IDH mutant cholangiocarcinoma. Hepatology 75, 1322–1337 (2022). 10.1002/hep.32424

[9]

Kelley, R. K., Bridgewater, J., Gores, G. J. & Zhu, A. X. Systemic therapies for intrahepatic cholangiocarcinoma. J. Hepatol. 72, 353–363 (2020). 10.1016/j.jhep.2019.10.009

[10]

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque et al.

The Lancet Oncology 2020 10.1016/s1470-2045(20)30109-1

[11]

Javle, M. et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol. Hepatol. 6, 803–815 (2021). 10.1016/s2468-1253(21)00196-5

[12]

Goyal, L. et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N. Engl. J. Med. 388, 228–239 (2023). 10.1056/nejmoa2206834

[13]

US Food and Drug Administration. FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion (2020).

[14]

US Food and Drug Administration. FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma (2021).

[15]

US Food and Drug Administration. FDA grants accelerated approval to futibatinib for cholangiocarcinoma. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma (2022).

[16]

Abou-Alfa, G. K. et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21, 796–807 (2020). 10.1016/s1470-2045(20)30157-1

[17]

US Food and Drug Administration. FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-advanced-or-metastatic-cholangiocarcinoma (2022).

[18]

Gravely, A. K., Vibert, E. & Sapisochin, G. Surgical treatment of intrahepatic cholangiocarcinoma. J. Hepatol. https://doi.org/10.1016/j.jhep.2022.01.004 (2022). 10.1016/j.jhep.2022.01.004

[19]

Wang, J., Loeuillard, E., Gores, G. J. & Ilyas, S. I. Cholangiocarcinoma: what are the most valuable therapeutic targets – cancer-associated fibroblasts, immune cells, or beyond T cells? Expert. Opin. Ther. Targets 25, 835–845 (2021). 10.1080/14728222.2021.2010046

[20]

Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma

Emilien Loeuillard, Jingchun Yang, EeeLN Buckarma et al.

Journal of Clinical Investigation 2020 10.1172/jci137110

[21]

Ruffolo, L. I. et al. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut 71, 1386–1398 (2022). 10.1136/gutjnl-2021-324109

[22]

Zhang, Q. et al. Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma. Cancer Discov. 11, 1248–1267 (2021). 10.1158/2159-8290.cd-20-0304

[23]

Gani, F. et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 23, 2610–2617 (2016). 10.1245/s10434-016-5101-y

[24]

Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules

Guoying Zhou, Dave Sprengers, Shanta Mancham et al.

Journal of Hepatology 2019 10.1016/j.jhep.2019.05.026

[25]

Ghidini, M. et al. Characterisation of the immune-related transcriptome in resected biliary tract cancers. Eur. J. Cancer 86, 158–165 (2017). 10.1016/j.ejca.2017.09.005

[26]

Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer

Lichun Ma, Maria O. Hernandez, Yongmei Zhao et al.

Cancer Cell 2019 10.1016/j.ccell.2019.08.007

[27]

Fabris, L., Sato, K., Alpini, G. & Strazzabosco, M. The tumor microenvironment in cholangiocarcinoma progression. Hepatology 73, 75–85 (2021). 10.1002/hep.31410

[28]

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies

Sarina A. Piha‐Paul, Do‐Youn Oh, Makoto Ueno et al.

International Journal of Cancer 2020 10.1002/ijc.33013

[29]

Buettner, S. et al. The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. Surgery 164, 411–418 (2018). 10.1016/j.surg.2018.05.002

[30]

Peng, D. et al. Lymphocyte to monocyte ratio predicts resectability and early recurrence of Bismuth-Corlette type IV hilar cholangiocarcinoma. J. Gastrointest. Surg. 24, 330–340 (2020). 10.1007/s11605-018-04086-9

[31]

Tsilimigras, D. I. et al. The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. HPB 22, 1667–1674 (2020). 10.1016/j.hpb.2020.03.011

[32]

Sun, D. et al. CD86+/CD206+ tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma. PeerJ 8, e8458 (2020). 10.7717/peerj.8458

[33]

Yuan, D. et al. Kupffer cell-derived TNF triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS. Cancer Cell 31, 771–789.e6 (2017). 10.1016/j.ccell.2017.05.006

[34]

WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited

Luke Boulter, Rachel V. Guest, Timothy J. Kendall et al.

Journal of Clinical Investigation 2015 10.1172/jci76452

[35]

Dwyer, B. J. et al. TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression. J. Hepatol. 74, 860–872 (2021). 10.1016/j.jhep.2020.11.018

[36]

Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 19, 108–119 (2018). 10.1038/s41590-017-0022-x

[37]

Xu, X. D. et al. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. Hepatobiliary Pancreat. Dis. Int. 15, 99–105 (2016). 10.1016/s1499-3872(15)60413-1

[38]

Meyer, C. et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63, 247–257 (2014). 10.1007/s00262-013-1508-5

[39]

Song, G. et al. Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma. Nat. Commun. 13, 1642 (2022). 10.1038/s41467-022-29164-0

[40]

Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis

Xuanwen Bao, Qiong Li, Jinzhang Chen et al.

Cancer Immunology Research 2022 10.1158/2326-6066.cir-21-1101

[41]

Keenan, B. P. et al. Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis. Cell Rep. 40, 111384 (2022). 10.1016/j.celrep.2022.111384

[42]

Tavazoie, M. F. et al. LXR/ApoE activation restricts innate immune suppression in cancer. Cell 172, 825–840.e18 (2018). 10.1016/j.cell.2017.12.026

[43]

Vonderheide, R. H. CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47–58 (2020). 10.1146/annurev-med-062518-045435

[44]

Diggs, L. P. et al. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. J. Hepatol. 74, 1145–1154 (2021). 10.1016/j.jhep.2020.11.037

[45]

Wabitsch, S. et al. Anti-PD-1 in combination with trametinib suppresses tumor growth and improves survival of intrahepatic cholangiocarcinoma in mice. Cell Mol. Gastroenterol. Hepatol. 12, 1166–1178 (2021). 10.1016/j.jcmgh.2021.05.011

[46]

Affo, S., Yu, L. X. & Schwabe, R. F. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu. Rev. Pathol. 12, 153–186 (2017). 10.1146/annurev-pathol-052016-100322

[47]

Brivio, S., Cadamuro, M., Strazzabosco, M. & Fabris, L. Tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer aggressiveness. World J. Hepatol. 9, 455–468 (2017). 10.4254/wjh.v9.i9.455

[48]

Sirica, A. E., Campbell, D. J. & Dumur, C. I. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma. Curr. Opin. Gastroenterol. 27, 276–284 (2011). 10.1097/mog.0b013e32834405c3

[49]

Sirica, A. E. & Gores, G. J. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology 59, 2397–2402 (2014). 10.1002/hep.26762

[50]

Fabris, L. et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 39, 63–78 (2019). 10.1111/liv.14098

Showing 50 of 161 references

Cited By

178

KAT2B inhibits cholangiocarcinoma proliferation by binding with histone demethylase KDM6B

Rongfang Qiu, Hui Meng · 2026

Biochimica et Biophysica Acta (BBA)...

Cancer-Associated Fibroblasts in Intrahepatic Cholangiocarcinoma

Silvia Affὸ, Laura Sererols-Viñas · 2025

The American Journal of Pathology

Cholangiocarcinoma-derived SPP1 drives tumor progression by inducing macrophage chemotaxis and M2 polarization

Tianze Wang, Pinsheng Han · 2025

International Immunopharmacology

Metrics

178

Citations

161

References

Details

Published: May 15, 2023
Vol/Issue: 20(7)
Pages: 470-486
License: View

Authors

Department of Medicine, Stanford School of Medicine, Palo Alto, California, USA

A

Angela Lamarca

Department of Oncology – Onco Health Institute Fundación Jiménez Díaz University Hospital Madrid Spain; Department of Medical Oncology, The Christie NHS Foundation, Manchester, Division of Cancer Sciences University of Manchester Manchester UK

Cite This Article

Sumera I. Ilyas, Silvia Affo, Lipika Goyal, et al. (2023). Cholangiocarcinoma — novel biological insights and therapeutic strategies. Nature Reviews Clinical Oncology, 20(7), 470-486. https://doi.org/10.1038/s41571-023-00770-1

Cholangiocarcinoma — novel biological insights and therapeutic strategies

You May Also Like